Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: A tissue microarray study

Clinical Cancer Research

Volumn 11, Issue 2 I, 2005, Pages 638-645

  Schneider Stock, Regine ^a   Boltze, Carsten ^b   Lasota, Jerzy ^c   Peters, Brigitte ^a   Corless, Chris L ^d   Ruemmele, Petra ^e   Terracciano, Luigi ^f   Pross, Matthias ^a   Insabato, Luigi ^g   Di Vizio, Dolores ^g   Iesalnieks, Igor ^e   Dirnhofer, Stefan ^f   Hartmann, Arndt ^e   Heinrich, Michel ^d   Miettinen, Markku ^c   Roessner, Albert ^a   Tornillo, Luigi ^f  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF REGENSBURG   (Germany)

^f UNIVERSITY OF BASEL   (Switzerland)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16; TUMOR MARKER;

ADULT; AGE; ARTICLE; FEMALE; FREQUENCY ANALYSIS; GASTROINTESTINAL STROMAL TUMOR; GENDER; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL; TISSUE MICROARRAY; TUMOR NECROSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CHILD; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EPITHELIOID CELLS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NECROSIS; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 19944427609     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Miettinen M, El-Rifai W, Sobin L H, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002;33:478-83.
2. Rubin BP, Singer S, Tsao C, et al. KIT activation is ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;81:8118-21.
3. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: kit activation and cytogenetic alterations. Hum Pathol 2002;33:484-95.
4. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10.
5. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumors. J Clin Oncol 2003;21:4342-9.
6. Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-65.
7. Rudolph P, Chiaravalli AM, Pauser U, et al. Gastrointestinal mesenchymal tumors-immunophenotypic classification and survival analysis. Virchows Arch 2002;441:238-48.
8. Lerma E, Oliva E, Tugues D, Prat J. Stromal tumours of the gastrointestinal tract: a clinicopathological and ploidy analysis of 33 cases. Virchows Arch 1994;424:19-24.
9. Sakurai S, Fukayama M, Kaizaki Y, et al. Telomerase activity in gastrointestinal stromal tumors. Cancer 1998;83:2060-6.
10. Günther T, Schneider-Stock R, Häckel C, et al. Telomerase activity and expression of hTRT and hTR in gastrointestinal stromal tumors in comparison with extragastrointestinal sarcomas. Clin Cancer Res 2000;6:1811-8.
11. El-Rifai W, Sarlomo-Rikala M, Andersson LC, Knuutila S, Miettinen M. DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res 2000;60:3899-903.
12. Gunawan B, Bergmann F, Hoer J, et al. Biological and clinical significance of cytogenetic abnormalities in low-risk and high-risk gastrointestinal stromal tumors. Hum Pathol 2003;33:316-21.
13. Lasota J, Dansonka-Mieszkowska A, Stachura T, et al. Gastrointestinal stromal tumors (GIST) with internal tandem duplications in 3′ end of kit juxtamembrane domain occur predominantly in stomach and generally have a favorable course. Mod Pathol 2003;16:1257-64.
14. Lasota J, Kopczynski J, Sarlomo-Rikala M, et al. KIT 1530ins6 mutation defines subset of predominantly malignant gastrointestinal stromal tumors (GIST) of intestinal origin. Hum Pathol 2003;34:1306-12.
15. House MG, Quo MZ, Efron DT, et al. Tumor suppressor gene hypermethylation as a predictor of gastric stromal tumor behavior. J Gastrointest Surg 2003;7:1004-14.
16. Koon N, Schneider-Stock R, Sarlomo-Rikala M, et al. Molecular targets for tumour progression in gastrointestinal stromal tumors. Gut 2004;53:235-40.
17. INK4 alterations in gastrointestinal stromal tumors. J Clin Oncol 2003;21:1688-97.
18. INK4 in human cancer. Proc Natl Acad Sci U S A 1994;91:11045-9.
19. Serrano M. The tumor suppressor protein p16INK4a. Exp Cell Res 1997;237:7-13.
20. Kawaguchi K, Oda Y, Saito T, et al. Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promotor methylation and poor prognosis. J Pathol 2003;201:487-95.
21. Gessner C, Liebers U, Kuhn H, et al. INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer. Eur Respir J 2002;19:134-40.
22. Hilton DA, Penney M, Evans B, Sanders H, Love S. Evaluation of molecular markers in low-grade diffuse astrocytomas: loss of p16 and retinoblastoma protein expression is associated with short survival. Am J Surg Pathol 2002;26:472-8.
23. Mäkitie AA, MacMillan C, Ho J, et al. Loss of p16 expression has prognostic significance in human nasophrayngeal carcinoma. Clin Cancer Res 2003;9:2177-84.
24. Esteller M, Gonzalez S, Risques RA, et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001;19:299-304.
25. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of hundreds of specimens. Nat Med 1998;4:844-7.
26. Lautsch E, von Weber S. Methoden und Anwendungen der Konfigurationsfrequenzanalyse. Weinheim: Psychologie Verlags Union; 1995.
27. Ueyama T, Guo KJ, Hashimoto H, Daimaru Y, Enjoji MA. Clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors. Cancer 1992;69:947-55.
28. Emory TS, Sobin LH, Lukes I, Lee DH, O'Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999;23:82-7.
29. Lasota J, Dansonka-Mieszkowska A, Sobin LH, Miettinen M. A great majority of GISTs with PDGFRA mutations represents gastric tumors of low or no malignant potential. Lab Invest 2004;84:874-83.
30. Sharpless NE, De Pinho RA. Telomeres, stem cells, senescence, and cancer. J Clin Invest 2004;113:160-8.
31. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumour suppression and cell mortality. Cell 1996;85:27-37.
32. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994;368:753-6.
33. Reed AL, Califano J, Caims P, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996;56:3630-3.
34. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8:27-32.
35. Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997;57:3126-30.
36. Liggett WH, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998;16:1197-206.
37. Rocco JW, Sidransky D. p16 (MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001;264:42-55.
38. Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16(CDKN2/MTS1 in human cancer. Nat Med 1995;1:685-92.